Cargando…

CD73 and PD-L1 as Potential Therapeutic Targets in Gallbladder Cancer

Gallbladder cancer (GBC) is one of the most common and aggressive biliary tract cancers with a dismal prognosis. Ongoing clinical trials are evaluating a few selected immune checkpoint inhibitors (ICIs) as monotherapy for the treatment of GBC patients. However, only a subset of patients benefits fro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cao, Lu, Bridle, Kim R., Shrestha, Ritu, Prithviraj, Prashanth, Crawford, Darrell H. G., Jayachandran, Aparna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836068/ https://www.ncbi.nlm.nih.gov/pubmed/35163489 http://dx.doi.org/10.3390/ijms23031565

Ejemplares similares

Combined Inhibition of TGF-β1-Induced EMT and PD-L1 Silencing Re-Sensitizes Hepatocellular Carcinoma to Sorafenib Treatment
por: Shrestha, Ritu, et al.
Publicado: (2021)

Prognostic Role of Immune Checkpoint Regulators in Cholangiocarcinoma: A Pilot Study
por: Cao, Lu, et al.
Publicado: (2021)

Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma
por: Shrestha, Ritu, et al.
Publicado: (2018)

Dual Targeting of Sorafenib-Resistant HCC-Derived Cancer Stem Cells
por: Shrestha, Ritu, et al.
Publicado: (2021)

TNF-α-mediated epithelial-to-mesenchymal transition regulates expression of immune checkpoint molecules in hepatocellular carcinoma
por: Shrestha, Ritu, et al.
Publicado: (2020)

Immune checkpoint molecules are regulated by transforming growth factor (TGF)-β1-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma
por: Shrestha, Ritu, et al.
Publicado: (2021)

Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer
por: Poddar, Arpita, et al.
Publicado: (2022)

Embryonic Chicken Transplantation is a Promising Model for Studying the Invasive Behavior of Melanoma Cells
por: Jayachandran, Aparna, et al.
Publicado: (2015)

CD39 and CD73 as Promising Therapeutic Targets: What Could Be the Limitations?
por: Battastini, Ana Maria Oliveira, et al.
Publicado: (2021)

Classification of gallbladder cancer by assessment of CD8(+) TIL and PD-L1 expression
por: Lin, Jianzhen, et al.
Publicado: (2018)

CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers
por: Harvey, Jerry B., et al.
Publicado: (2020)

Targeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy
por: de Leve, Simone, et al.
Publicado: (2019)

CD73 and PD-L1 dual blockade amplifies antitumor efficacy of SBRT in murine PDAC models
por: Ye, Jian, et al.
Publicado: (2023)

Identifying and targeting determinants of melanoma cellular invasion
por: Jayachandran, Aparna, et al.
Publicado: (2016)

PD-L1 for gallbladder cancer: case report
por: Li, Xiaodong, et al.
Publicado: (2020)

Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL
por: Zhang, Tingting, et al.
Publicado: (2022)

Pregnancy associated plasma protein-A links pregnancy and melanoma progression by promoting cellular migration and invasion
por: Prithviraj, Prashanth, et al.
Publicado: (2015)

Prognostic impact of CD73 expression and its relationship to PD-L1 in patients with radically treated pancreatic cancer
por: Tahkola, Kyösti, et al.
Publicado: (2020)

Anti–PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC
por: Tu, Eric, et al.
Publicado: (2022)

PD-1/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas
por: Xie, Wei, et al.
Publicado: (2022)

Targeting CD73 in the tumor microenvironment with MEDI9447
por: Hay, Carl M., et al.
Publicado: (2016)

Aberrant pregnancy-associated plasma protein-A expression in breast cancers prognosticates clinical outcomes
por: Prithviraj, Prashanth, et al.
Publicado: (2020)

Epithelial-to-mesenchymal plasticity of cancer stem cells: therapeutic targets in hepatocellular carcinoma
por: Jayachandran, Aparna, et al.
Publicado: (2016)

Additive Effect of CD73 Inhibitor in Colorectal Cancer Treatment With CDK4/6 Inhibitor Through Regulation of PD-L1
por: Noh, Ji-Yoon, et al.
Publicado: (2022)

CD73 downregulation by EGFR-targeted liposomal CD73 siRNA potentiates antitumor effect of liposomal doxorubicin in 4T1 tumor-bearing mice
por: Soleimani, Anvar, et al.
Publicado: (2022)

The Roles of CD73 in Cancer
por: Gao, Zhao-wei, et al.
Publicado: (2014)

Two-photon dual imaging platform for in vivo monitoring cellular oxidative stress in liver injury
por: Wang, Haolu, et al.
Publicado: (2017)

Single-cell RNA sequencing reveals distinct cellular factors for response to immunotherapy targeting CD73 and PD-1 in colorectal cancer
por: Kim, Miok, et al.
Publicado: (2021)

Heat Shock Proteins and PD-1/PD-L1 as Potential Therapeutic Targets in Myeloproliferative Neoplasms
por: De Almeida, Steven, et al.
Publicado: (2020)

CD73 is associated with poor prognosis in HNSCC
por: Ren, Zhen-Hu, et al.
Publicado: (2016)

Transketolase-like 1 ectopic expression is associated with DNA hypomethylation and induces the Warburg effect in melanoma cells
por: Jayachandran, Aparna, et al.
Publicado: (2016)

The Clinical Significance of CD73 in Cancer
por: Bach, Niklas, et al.
Publicado: (2023)

The distinct role of CD73 in the progression of pancreatic cancer
por: Zhou, Liangjing, et al.
Publicado: (2019)

Hedgehog signaling pathway is a potential therapeutic target for gallbladder cancer
por: Matsushita, Shojiro, et al.
Publicado: (2014)

The Ecto-5′nucleotidase/CD73 Mediates Leishmania amazonensis Survival in Macrophages
por: Bajracharya, Bijay, et al.
Publicado: (2022)

Focus on PD-1/PD-L1 as a Therapeutic Target in Ovarian Cancer
por: Dumitru, Adrian, et al.
Publicado: (2022)

Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity
por: Piovesan, Dana, et al.
Publicado: (2022)

Exploring CD39 and CD73 Expression as Potential Biomarkers in Prostate Cancer
por: Gardani, Carla Fernanda Furtado, et al.
Publicado: (2023)

Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR
por: Ploeg, Emily Maria, et al.
Publicado: (2023)

Epidemiology of gallbladder cancer
por: Rawla, Prashanth, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0l3kuhpjn6kcaqbt5dabgc433k